Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Nasim MavaddatAntonis C AntoniouThea M MooijMaartje J HooningBernadette A Heemskerk-Gerritsennull nullCatherine NoguèsMarion Gauthier-VillarsOlivier CaronPaul GestaPascal PujolAlain Lortholarynull nullDaniel BarrowdaleDebra FrostD Gareth EvansLouise IzattJulian AdlardRos EelesCarole BrewerMarc TischkowitzAlex HendersonJackie CookDiana Ecclesnull nullKlaartje van EngelenMarian J E MouritsMargreet G E M AusemsLinetta B KoppertJohn L HopperEsther M JohnWendy K ChungIrene L AndrulisMary B DalySaundra S Buysnull nullJavier BenitezTrinidad CaldesAnna JakubowskaJacques SimardChristian F SingerYen TanEdith OlahMarie NavratilovaLenka ForetovaAnne-Marie GerdesMarie-José Roos-BlomFlora E Van LeeuwenBrita ArverHåkan OlssonRita K SchmutzlerChristoph EngelKarin KastKelly-Anne PhillipsMary Beth TerryRoger L MilneDavid E GoldgarMatti A RookusNadine AndrieuDouglas F Eastonnull nullnull nullnull nullPublished in: Breast cancer research : BCR (2020)
We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.
Keyphrases